Minirin Melt (Desmopressin)

Desmopressin mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that inserts aquaporin‑2 water channels into the duct lining, allowing more water to be reabsorbed and producing concentrated urine. In hemophilia A, it prompts endothelial cells to release stored factor VIII.

The appropriate dose of Minirin Melt is individualized by the prescribing clinician based on the patient’s condition, age, renal function, and response to therapy. Dosage adjustments are made according to clinical monitoring of urine output, serum sodium, and, when relevant, factor VIII levels.

Safety data for Minirin Melt in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Minirin Melt, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minirin Melt delivers desmopressin via a sublingual melt, offering rapid absorption and ease of use compared with oral tablets or nasal sprays. Its selective V2‑receptor activity provides antidiuretic effects with fewer vasoconstrictive actions than some older vasopressin analogues, making it a preferred option for many patients.

Store Minirin Melt at ambient temperature, preferably below 25 °C. Keep the melt tablets in their original blister pack, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Minirin Melt is placed under the tongue and allowed to dissolve completely without swallowing. The sublingual route enables direct absorption into the bloodstream, bypassing the gastrointestinal tract. Patients should avoid eating or drinking for a few minutes after administration to ensure optimal uptake.

The most serious risks include severe hyponatremia, which can lead to seizures or coma, and thromboembolic events such as deep‑vein thrombosis. Rapid weight gain, pulmonary edema, or any sudden neurological changes should prompt immediate medical evaluation.

Minirin Melt should be avoided in patients with known hypersensitivity to desmopressin, uncontrolled hyponatremia, severe renal impairment, or those taking other potent antidiuretic agents unless specifically directed by a physician. Caution is also advised for individuals with a history of water intoxication or certain cardiac conditions.